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Abstract
Background: The display of binding ligands, such as recombinant antibody fragments, on the
surface of filamentous phage makes it possible to specifically attach these phage particles to target
cells. After uptake of the phage, their internal single-stranded DNA is processed by the host cell,
which allows transient expression of an encoded eukaryotic gene cassette. This opens the
possibility to use bacteriophage as vectors for targeted gene therapy, although the transduction
efficiency is very low.
Results: Here we demonstrate the display of an anti-CD30 single chain variable fragment fused to
the major coat protein pVIII on the surface of bacteriophage. These phage particles showed an
improved binding and transduction efficiency of CD30 positive Hodgkin-lymphoma cells, compared
to bacteriophage with the anti-CD30 single chain variable fragment fused to the minor coat protein
pIII.
Conclusion: We can conclude from the results that the postulated multivalency of the anti-CD30-
pVIII displaying bacteriophage combined with disseminated display of the anti-CD30 scFv on the
whole particle surface is responsible for the improved gene transfer rate. These results mark an
important step towards the use of phage particles as a cheap and safe gene transfer vehicle for the
gene delivery of the desired target cells via their specific surface receptors.
Background
The specific in or ex vivo transduction of cancerous,
infected or malfunctioning cells with pro-apoptotic,
defence or restoring genes is a promising approach for the
treatment of patients. However, gene therapy continues to
present obstacles, regarding safety, transduction efficiency
and specificity. Most gene delivery systems are based on
animal viral vectors, which are efficient on one hand, but
may include the risk of intrinsic toxicity and are costly to
manufacture. In addition to developing safer viral vectors,
scientists began modifying bacteriophage particles for
gene delivery purposes [1,2]. For example, filamentous
bacteriophage libraries, consist of up to 1010 unique
phage particles; each displaying a different binding ligand
on its surface and encapsulating the corresponding
eukaryotic cDNA. These libraries are commonly used for
the selection of novel antigen-specific binding mole-
cules[3]. Furthermore, it is possible to select for ligand-
bound phage being internalised by the target cell after
receptor-binding [4,5]. If a eukaryotic gene cassette is
encoded in the phagemid vector, a small percentage of tar-
get cells will express this gene [2,6,7]. Thus, bacteriophage
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delivery vectors. They have no natural tropism for eukary-
otic cells, nor do they integrate into the cell's genome.
A filamentous bacteriophage containing a phagemid vec-
tor (herein after referred to as "phagemid particle")
encodes only the gene for a surface fusion protein, an anti-
biotic resistance gene and an amplification and packaging
signal, but lacks the genes for all other bacteriophage pro-
teins. In order to produce functional phagemid particles,
E. coli transformed with the phagemid vector have to be
superinfected with helper phage (phage rescue), which
contribute the missing proteins for the phagemid particle
assembly in the periplasm of E. coli. Phagemid particles
are easy to genetically modify in terms of targeting to a
specific receptor-bearing cell population. As phagemid
vectors are relatively small in size compared to full size
phage vectors, they are capable of carrying larger foreign
DNA sequences. However, a major obstacle of using bac-
teriophage as gene transfer vehicles is their low transduc-
tion efficiency, which relies on gene transfer and
expression. Gene transfer efficiency generally depends on
the binding affinity of the ligand and the intracellular traf-
ficking of the internalized receptor-bound phage, includ-
ing endosomal escape and capsid breakdown. Moreover,
processing of the single-stranded phage DNA, including
conversion into double-stranded DNA and nuclear locali-
zation, is a critical factor [8].
Commonly, the displayed ligand is fused to the minor
coat protein pIII (5 copies per phage). Ligands can be dis-
played either monovalently or multivalently, depending
on the helper phage system being used. The importance of
this factor has been demonstrated by Larocca et al. (2001)
[9] in comparing the transduction efficiency of epidermal
growth factor receptor (EGFR)-positive target cells with
bacteriophage containing a green fluorescence protein
(GFP) gene and displaying either monovalently or multi-
valently the EGF molecule. The multivalency of the EGF,
fused to the minor coat protein pIII on the phage particles,
increased transduction efficiency by 5-fold. Similar effects
have been shown by Poul and Marks (1999) using a pIII-
displayed anti-ErbB2 scFv.
Moreover, it has been demonstrated that phages display-
ing ligands fused to their major coat protein pVIII (2700
copies per phage) are able to bind to cell surface receptors,
be internalized and processed inside mammalian cells
[10] leading to marker gene expression [7]. It is generally
believed that the wild type to fusion protein ratio of pVIII
displaying phage is inversely related to the size of the dis-
played ligand, making it difficult to functionally express
larger proteins on the phage surface [11]. Nevertheless, it
has been shown that this correlation is not so stringent.
Malik et al. (1996) demonstrated that Fab fragments and
enzymes can be displayed on pVIII, but with a frequency
of less than 1% [12].
We were interested in developing a gene delivery vector
for the specific transduction of Hodgkin/Reed-Sternberg
cells, the malignant cell type of Hodgkin's lymphoma.
The CD30 receptor has been exploited as Hodgkin-lym-
phoma associated antigen in recent experimental thera-
peutic strategies [13,14]. Antibodies bound to CD30 are
internalized by clathrin-mediated endocytosis and traffic
to the lysosome [15]. Regarding this internal trafficking of
CD30-bound complexes as a prerequisite for gene trans-
fer, we generated a phagemid vector that encodes an anti-
CD30 scFv-pVIII fusion protein and a eukaryotic CMV-
EGFP gene cassette. Out of this vector we produced small,
anti-CD30 phagemid particles, capable of delivering
EGFP as a reporter gene for transduction. We chose the
major coat protein pVIII as the fusion partner for the dis-
play of the anti-CD30 scFv Ki-4 [14]. Fusion with pVIII as
an alternative to the widely used minor coat protein pIII
should increase the multivalency of the scFv-display and
demonstrate the feasibility of displaying relatively big
molecules, like scFvs (27 kDa) on pVIII.
Results
Construction of the anti-CD30 gene transfer phagemid 
vectors
The anti-CD30 scFv Ki-4 has been selected from a Ki-4
hybridoma-derived phage display library via cell panning
on L540 Hodgkin cells as previously described [14]. The
eukaryotic CMV-EGFP gene cassette was excised from the
pEGFP-N2 expression vector and ligated into the
phagemid vector pCANTAB6-Ki-4, resulting in the vector
pC6-Ki-4(EGFP). Transformation of E. coli TG-1 and sub-
sequent packaging of the pC6-Ki-4(EGFP) phagemid vec-
tor with M13 helper phage leads to M13-pC6-Ki-4(EGFP)
phagemid particles with the Ki-4 scFv monovalently dis-
played as a fusion protein with the minor coat protein pIII
(Fig. 1a). An exchange of the pIII gene of pC6-Ki-4 with
the pVIII gene from the M13 genome and the insertion of
the CMV-EGFP gene cassette, resulted in the phagemid
vector pAK8-Ki-4(EGFP). Rescuing of phagemid particles
with this phagemid vector will produce the M13-pAK8-Ki-
4(EGFP) phagemid particles with Ki-4 scFv displayed in
multiple copies on their surface (Fig. 1b). As a control, the
Ki-4 scFv gene was deleted from the pAK8-Ki-4(EGFP)
phagemid vector, to produce the phagemid particles M13-
pAK8(EGFP) displaying no anti-CD30 scFv on their sur-
face, but containing a functional eukaryotic EGFP expres-
sion cassette (Fig. 1c).
Detection of Ki-4 scFv fused to bacteriophage coat protein 
pVIII
After superinfection of the phagemid vector containing E.
coli clones with helper phage, the phagemid particlesPage 2 of 11
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phagemid single-stranded DNA with the major coat pro-
tein (pVIII) and the minor coat proteins (pIII, pVI, pVII
and pIX). During this process, the N-terminal signal
sequences of the coat proteins pIII and pVIII are cleaved
leaving the N-terminal part of these proteins outside of
the bacteriophage capsid and accessible for binding inter-
actions. The predicted size of the major coat protein pVIII
(5 kDa) fused with the Ki-4 scFv (27 kDa) is 32 kDa (Ki-
4-pVIII). In Western blot analysis this fusion protein was
detected in M13-pAK8-Ki-4(EGFP) and not in the control
M13-pAK8(EGFP) phagemid particles (Fig. 2).
Specific CD30 binding of Ki-4 scFv-displaying phage
To demonstrate that phagemid particles displaying the Ki-
4 scFv specifically bind CD30, an enzyme-linked immuno
sorbent assay (ELISA) was performed, coating wells with
recombinant CD30 and incubating them with 4 × 1010
phagemid particles. A strong interaction of the anti-CD30
Ki-4 scFv-displaying phagemid particles M13-pAK8-Ki-
4(EGFP) and M13-pC6-Ki-4(EGFP) with the coated CD30
was detected. The control phagemid particle M13-
pAK8(EGFP) and phagemid particles incubated in non-
coated wells did not bind (Fig. 3). The binding of M13-
pAK8-Ki-4(EGFP) to the CD30 antigen was stronger than
the binding of the M13-pC6-Ki-4(EGFP).
To demonstrate the cell binding specificity of the anti-
CD30 phagemid particles, FACS analyses were performed.
Confirming the ELISA results, the Ki-4 scFv displaying
phagemid particles bound only to the CD30-positive,
Hodgkin-derived cell lines L1236, L540, L428 and KMH-
2 and not to the CD30-negative multiple myeloma cell
line U266 and the Burkitt Lymphoma cell line BL38. The
control phagemid particle M13-pAK8(EGFP) did not
show binding to any cell line. Furthermore, the FACS
analysis revealed that M13-pAK8-Ki-4(EGFP) binding to
the target cells is consistently stronger than the binding of
the M13-pC6-Ki-4(EGFP) phagemid particles (Fig. 4).
The incubation of the CD30-positive cells with the anti-
CD30 scFv-displaying phagemid particle M13-pAK8-Ki-
4(EGFP) leads to additional cluster formation of the cells
after 24 hours, in contrast to the M13-pC6-Ki-4(EGFP)
phagemid particles (Fig. 5). No cluster formation was seen
with CD30-negative cells incubated with M13-pAK8-Ki-
4(EGFP).
Specific gene transfer of CD30-positive cells by targeted 
bacteriophage
We performed competition assays to determine if CD30-
binding phagemid particles are capable of antigen-specific
gene delivery of a EGFP reporter gene. 5 × 104 CD30-pos-
itive L1236 cells were incubated with 2 × 1011 M13-pAK8-
Ki-4(EGFP) phagemid particles in the absence or presence
of 30 nM or 300 nM of the parental monoclonal antibody
Ki-4, respectively (Fig. 6a). In the absence of the competi-
tor about 0.1% of the cells show EGFP expression demon-
Phagemid vectors pCANTAB6-Ki-4(EGFP), pAK8-Ki-4(EGFP) and pAK8(EGFP)Figure 1
Phagemid vectors pCANTAB6-Ki-4(EGFP), pAK8-Ki-4(EGFP) and pAK8(EGFP). Schematic drawing of phagemid 
vectors and deduced phagemid particles used for gene transfer. pCANTAB6-Ki-4(EGFP) (a) and pAK8-Ki-4(EGFP) (b) contain 
the pIII signal sequence (S) adjacent to the Ki-4 scFv gene. pCANTAB6-Ki-4(EGFP), pAK8-Ki-4(EGFP) and pAK8(EGFP) (c) 
contain the enhanced green fluorescence protein gene (EGFP), under the control of a cytomegalovirus promoter (CMV) and 
terminated by a poly adenylation site (pA), as well as an M13 origin of replication site, with a DNA packaging signal sequence 
(M13 ori), an ampicillin resistance gene (amp-r) and an E. coli origin of replication site (E. coli ori).
pIII pVIII 
ssDNA 
Ki-4 scFv b 
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monoclonal antibody Ki-4, the number of transduced
cells is clearly reduced in a dose dependent manner, prov-
ing the antigen-specificity of the gene transfer. To further
demonstrate antigen-specificity and evaluate transduction
efficiency, 5 × 104 of the CD30-positive L1236, L428,
L540 and KMH-2 cells or the CD30-negative BL38 or
U266 cell lines were incubated for 96 hours with 2 × 1012
phagemid particles M13-pAK8(EGFP), M13-pAK8-Ki-
4(EGFP) or M13-pC6-Ki-4(EGFP), respectively. The per-
centage of living cells expressing the eukaryotic gene cas-
sette CMV-EGFP was determined by FACS analysis after
propidium iodide staining as depicted in Fig. 6b. As
shown in Fig. 6c the L1236 cells remain untransduced
when incubated with the control phagemid particles
M13-pAK8(EGFP). Phagemid particles displaying the Ki-4
scFv fused to the coat protein pIII (M13-pC6-Ki-4(EGFP))
minimally transduced the L1236 cells (0.8%). In contrast,
L1236 cells incubated with the same amount of M13-
pAK8-Ki-4(EGFP) phagemid particles displaying Ki-4
scFv-pVIII fusion proteins, the transduction efficiency was
significantly increased to approximately 5%. The superior
transduction efficiency of the M13-pAK8-Ki-4(EGFP)
phagemid particles was also seen with the other CD30-
positive cell lines, as summarized in Fig. 6d. No transduc-
tion could be seen with the CD30-negative cell lines BL38
or U266 using these phagemid particles.
Discussion and Conclusion
Use of bacteriophage as vectors for targeted gene transfer
into eukaryotic cells is an alternative method to circum-
vent some of the problems occurring with the established
viral vectors. Bacteriophage have no natural tropism for
eukaryotic cells but can be targeted towards specific cell
surface receptors by displaying appropriate binding lig-
ands, such as peptides or antibody fragments. Internalized
by receptor-mediated endocytosis, their packaged single-
stranded DNA is further processed (mechanisms not fully
understood), leading to the expression of encoded genes
under eukaryotic promoters [6]. The ease with which one
can target, modify, produce and purify these phage makes
them a valuable tool for antigen-specific cell transduction.
Here, we describe the generation of anti-CD30 targeted
phagemid particles, specifically binding and transducing
CD30-positive cells. For this purpose, the anti-CD30 Ki-4
scFv gene has been genetically fused either to the major
coat protein pVIII (pAK8-Ki-4(EGFP)) or the minor coat
protein pIII (pC6-Ki-4(EGFP)) in a phagemid vector,
which also encodes an EGFP gene under the control of a
CMV promoter. The expression of the Ki-4 scFv-pVIII
fusion protein was determined by Western blot analysis
(Fig. 2) and ELISA experiments with recombinant CD30
antigen demonstrating the specific binding of the Ki-4
scFv displaying phagemid particles (Fig. 3). Additionally,
phage displaying the Ki-4 scFv showed a specific binding
to CD30-bearing cells in FACS analyses. Binding affinity
of the M13-pAK8-Ki-4(EGFP) phagemid particles to
CD30 antigen and CD30 receptor-bearing cells was
always higher, compared to the M13-pC6-Ki-4(EGFP)
phagemid particles. Provided that scFvs fused to the pIII
coat protein have the same binding affinity as pVIII-fusion
proteins, this difference could be explained by a multiva-
Specific anti-CD30 binding of Ki-4 scFv-displaying phagemid particlesFigur 3
Specific anti-CD30 binding of Ki-4 scFv-displaying 
phagemid particles. CD30 antigen (50 ng/ml) was coated 
to ELISA MaxiSorp plates and 4 × 1010 phagemid particles 




























Detection of displayed Ki-4 scFv fusion proteinFigure 2
Detection of displayed Ki-4 scFv fusion protein. West-
ern blot analysis of 8 × 1010 (lanes 1 and 3) or 4 × 1010 (lanes 
2 and 4) of purified phagemid particles M13-pAK8-Ki-
4(EGFP) (lanes 1 and 2) or M13-pAK8(EGFP) (lanes 3 and 4), 
respectively. The fusion protein was detected using anti-
M13-pVIII- and goat-anti-mouse-HRP-antibodies. Arrow indi-
cates pVIII-scFv fusion protein.
M      1         2      M      3        4
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Cell binding studies of M13-pAK8-Ki-4(EGFP), M13-pC6-Ki-4(EGFP) and M13-pAK8(EGFP) phagemid particlesFigure 4
Cell binding studies of M13-pAK8-Ki-4(EGFP), M13-pC6-Ki-4(EGFP) and M13-pAK8(EGFP) phagemid parti-
cles. 2,5 × 105 of indicated cells (filled black) were incubated with 2 × 1012 phagemid particles (M13-pAK8-Ki-4(EGFP) black 
line, M13-pC6-Ki-4(EGFP) gray line or M13-pAK8(EGFP) dark gray line) and subsequently incubated with mouse anti-M13 IgG 
and Alexa Fluor 488-conjugated anti-mouse IgG antibody. Mean fluorescence intensity of cells was analyzed by fluorescence-











































































































































BMC Molecular Biology 2008, 9:37 http://www.biomedcentral.com/1471-2199/9/37
Page 6 of 11
(page number not for citation purposes)
Cluster formation of CD30+ cells incubated with M13-pAK8-Ki-4(EGFP)Figure 5
Cluster formation of CD30+ cells incubated with M13-pAK8-Ki-4(EGFP). 5 × 104 L1236, L428 and CD30-negative 
BL38 cells were incubated with 5 × 1011 M13-pC6-Ki-4(EGFP) or M13-pAK8-Ki-4(EGFP) phagemid particles for 24 hrs, respec-
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Specific gene delivery of CD30 positive cell linesFigure 6
Specific gene delivery of CD30 positive cell lines. Gene delivery specificity was demonstrated via competition experi-
ment. (a) L1236 cells were incubated with M13-pAK8-Ki-4(EGFP) phagemid particles in the absence or presence of mono-
clonal antibody (moab) Ki-4. Representative sections were photographed with 10 × objective using fluorescence microscopy. 
Transduction efficiency was quantified by FACS analysis after 96 hours. Indicated cell lines were incubated with M13-pAK8-
Ki4(EGFP), M13-pCANTAB-Ki4(EGFP) or M13-pAK8(EGFP) phagemid particles, respectively. (b) A homogenous cell popula-
tion (P1) was gated in forward (FSC-H) by right-angle light (SSC-H) scatter plots and subsequently gated for living cells (P2) in 
FSC-H by propidium iodide (PI-A) channel dot plot. The living cells were finally analyzed for EGFP-expression in PI-A versus 
green fluorescence (FITC-A) channel dot plot, setting the gate at 0.05% of transduced cells incubated with the control 
phagemid particles M13-pAK8(EGFP). (c) Representative analysis of the L1236 cell line, incubated with M13-pAK8(EGFP), 
M13-pCANTAB6-Ki4(EGFP) or M13-pAK8-Ki4(EGFP) phagemid particles, respectively. Cells were analyzed for EGFP expres-
sion as described above. (d) Summarized results of transduction experiments with different cell lines in percentage of EGFP-
expressing cells. Statistical significance was analysed according to the Student's one-tailed t test. p-values < 0.05, < 0.01 and < 




a   L1236 + 2 x 1011 M13-pAK8-Ki-4(EGFP)
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Ki-4(EGFP) phagemid particles indicating a binding avid-
ity effect. The multivalent display of the scFv on the M13-
pAK8-Ki-4(EGFP) phagemid particles is also supported by
the fact that these phagemid particles are able to induce
additional cluster formation of CD30-positive cells (Fig.
5). This phenomena was not seen with the supplement of
M13-pC6-Ki-4(EGFP) phagemid particles or the addition
of the M13-pAK8-Ki-4(EGFP) phagemid particles to the
CD30-negative cell line BL38, but has been observed pre-
viously by the addition of monoclonal Ki-4 IgG antibody
to CD30-positive cells (data not shown).
The transduction experiments with different cell lines
revealed that anti-CD30 scFv-displaying phagemid parti-
cles are able to transduce CD30 receptor-bearing cells. The
addition of the parental monoclonal antibody Ki-4 signif-
icantly reduced the amount of CD30-positive L1236 cells
transduced by the M13-pAK8-Ki-4(EGFP) phagemid par-
ticles (Fig. 6a). There was no unspecific transduction of
CD30-negative cells, nor did control phagemid particles
M13-pAK8(EGFP) transduce the CD30-positive cells (Fig.
6d). This indicates that CD30 antigen on the targeting cell
lines is required for transduction with anti-CD30
phagemid particles and establishes the high specificity of
these gene transfer particles. Incubation of the target cells
with the M13-pAK8-Ki-4(EGFP) phagemid particles led to
a maximum transduction rate of 5%, a rate approximately
10-fold higher compared to the M13-pC6-Ki-4(EGFP)
phagemid particles. This enabled a direct comparison of
pVIII- and pIII- fusion protein display for receptor-specific
gene transfer. Although there is a postulated avidity effect
responsible for the stronger binding of the M13-pAK8-Ki-
4(EGFP) phagemid particles to recombinant CD30 and
CD30-positive cells compared to the M13-pC6-Ki-
4(EGFP) phagemid particles, this significant difference in
transduction efficiency was somewhat surprising. Other
groups using monovalent pIII-display with transduction
efficiencies of 1–4% were able to increase the efficiencies
up to 10% by using multivalent pIII-display [6,9].
It has been described that CD30 receptor is being internal-
ized by clathrin-mediated endocytosis, maturing to lyso-
somes and that cross-linking of CD30 receptors by
monoclonal antibodies enhances this trafficking at least
by 3-fold [15]. In accordance with our results, this sup-
ports our hypothesis that pVIII-based display of scFvs is
multivalent, leading to increased internalization and
transduction efficiency of CD30-bearing cells. Although it
has been shown that multivalent scFv-pIII display on bac-
teriophage is possible and increases transduction effi-
ciency [9], our approach serves as an alternative or even
superior system, especially if the internalization depends
on multipoint 'zipper' contacts of the phage with the cell
surface receptors. A multivalent display on pVIII may pro-
vide an increased binding and phage uptake because pVIII
fusion proteins are spread over the surface of the phage, in
contrast to pIII fusion proteins, which are focused on the
tip of the phage. This so-called 'disseminated display'
would also explain why M13-pAK8-Ki-4(EGFP), in con-
trast to the M13-pC6-Ki-4(EGFP) phagemid particles, are
able to connect CD30-positive cells leading to cluster for-
mation (Fig. 5). This also explains the stronger binding
activity of the M13-pAK8-Ki-4(EGFP) phagemid particles
(Fig. 4) and the higher transduction rate (Fig. 6d). How-
ever, this potential cross-linking of cells by single M13-
pAK8-Ki-4(EGFP) phagemid particles does not prevent
internalization of other M13-pAK8-Ki-4(EGFP) phagemid
particles, because simultaneous binding of receptors on
one cell is even more likely than cross linking of receptors
on separate cells.
The feasibility of displaying molecules as large as scFvs
(27 kDa) on the major coat protein raises the possibility
of generating bispecific phagemid particles rescued from
E. coli, encoding an additional pIII- or pVIII-fusion pro-
tein, thereby increasing specificity and avidity of the cell-
targeting phagemid particle.
The unequal transduction rates of the different CD30-pos-
itive cell lines with the M13-pAK8-Ki-4(EGFP) phagemid
particles are not directly explainable by their individual
CD30 receptor densities. For example, cell line L1236
showed only a moderate binding of the anti-CD30
phagemid particles in FACS analysis compared to the
L540 cell line(Fig. 4), but revealed the highest EGFP-
expression rate (Fig. 6c). This demonstrates that the effi-
ciency of the gene transfer seems to be dependent on cell
line-specific trafficking of the bacteriophage after binding.
Because the gene transfer efficiency of targeted bacteri-
ophage is in general still very low, it seems to be necessary
to further optimize trafficking, DNA processing and
nuclear localization of the phagemid DNA. So far, satisfy-
ing transduction rates (30–45%) with bacteriophage have
been reached only in vitro by genotoxic treatment [16].
To our knowledge, this is the first approach demonstrat-
ing a potential advantage of the major coat protein pVIII
as fusion partner for the display of scFvs in gene transfer
experiments, compared to the commonly used minor coat
protein pIII. Furthermore, it is the first approach generat-
ing a CD30-specific gene transfer vector to be used for the
transduction of Hodgkin-, Reed Sternberg cells. A possible
application of this system would be the specific induction
of apoptosis in these cells. It is believed that cancer cells
are on the verge of apoptosis, containing processed effec-
tor caspases. At the same time, they also express inhibitor
of apoptosis proteins (IAPs), which can not be neutralized
due to malfunctioning apoptotic pathways [17]. It has
been demonstrated that overexpression of second mito-Page 8 of 11
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derived cell lines blocks X-linked IAPs activation [18], and
therefore would make a promising candidate gene for res-
toration of the apoptotic pathway in Hodgkin's disease
via targeted gene therapy. Provided that the transduction
efficiency of CD30-specific bacteriophage is further
increased by additional molecular modifications, they can
potentially serve as specific, safe, cheap and efficient gene
therapy vectors for in and ex vivo applications. This is sup-
ported by the fact that tumor treatment with targeted bac-
teriophage in vivo has been demonstrated recently [19].
Methods
Cells and Bacteria
The Morbus Hodgkin derived cell lines L540 [20], L1236
[21], L428 [22], KMH-2 [23], the Burkitt lymphoma cell
line BL38 [24] and the multiple myeloma cell line U266
[25] were cultivated in RPMI 1640 supplemented with
10% (v/v) heat inactivated fetal calf serum (FCS), 50 µg/
ml Penicillin, 100 µg/ml Streptomycin and 2 mM L-
glutamine. All cells were cultured at 37°C in a 5% CO2
atmosphere. E. coli TG-1 (K12 ∆(lac-pro), supE, thi,
hsdD5F'traD36, proA+B+, lacIq, lacZ∆M15) were provided
by CAT (Cambridge, UK).
Plasmids
pAK8 was cloned by exchanging the minor coat protein
pIII gene from pCANTAB6-Ki-4 phagemid vector [14]
with the major coat protein pVIII gene from KM13-K07
helper phage genome. pVIII was amplified by PCR using
the primer pair pVIII NotI sense 5'-ATC GCG GCC GCA
GAG GGT GAC CCC-3' and pVIII EcoRI antisense 5'-ACT
GAA TTC TTA TCA GCT TGC TTT-3'. The PCR product was
digested with NotI/EcoRI and ligated into pCANTAB6-Ki4
phagemid vector. pAK8-Ki-4 and pCANTAB6-Ki-4
phagemid vectors were digested with restriction enzyme
EheI creating blunt ends and ligated with the reporter gene
cassette CMV-EGFP, obtained from pEGFP-N3 plasmid
(Clontech, USA) that had been digested with VspI/BspT1
and treated with T4 DNA polymerase to produce blunt
ends. The resulting phagemid vectors were pAK8-Ki-
4(EGFP) and pC6-Ki-4(EGFP). The control phagemid vec-
tor pAK8(EGFP) was constructed by excising the Ki-4 scFv
gene via PvuII digest.
Phagemid particle preparation and purification
For production of M13-pAK8-Ki4(EGFP), M13-pC6-
Ki4(EGFP) and M13-pAK8(EGFP) phagemid particles,
phagemid vector transformed overnight culture of E. coli
TG-1 were grown and used to inoculate 50 ml 2xYT + 100
µg/ml ampicillin at a ratio of 1:100 at 37°C with vigorous
shaking (220 rpm) to an OD600 of 0.5. 5 ml of the culture
were infected with helper phage (KM13-K07) at a ratio of
4 phage per bacterium and incubated at 37°C in a water
bath without shaking for 30 min and 30 min at 37°C with
shaking (220 rpm). Bacteria were spun down, resus-
pended in 25 ml 2xYT + 100 µg/ml ampicillin + 50 µg/ml
kanamycin and shaken overnight at 30°C. After removing
of bacteria by centrifugation (20 min at 4400 g) superna-
tant was transferred into fresh bottles and phage were
purified by two rounds of standard polyethylene glycol
(PEG) precipitation as described [26]. The final phage pel-
let was resuspended in 1.5 ml PBS. Phage titers in colony
forming units (cfu) were determined by photometrical
absorption at 269 nm as described [27].
ELISA
Multi-well Maxisorp plates (Nunc, Germany) were coated
for 1 h at room temperature with 50 µl of recombinant
CD30 antigen (R&D Systems, USA) at a concentration of
10 µg/ml in bicarbonate buffer, pH 9.6. After discarding
the coating solution, wells were washed 5 × with 200 µl
PBS-0.1% Tween and incubated for 1 h with blocking
solution (PBS-4% skimmed milk powder). After washing,
50 µl of M13-pAK8-Ki-4(EGFP), M13-pC6-Ki-4(EGFP)
and M13-pAK8(EGFP) phagemid particles (4 × 1010 cfu)
were added to the wells and allowed to bind for one hour.
Plates were washed 10 × with 200 µl PBS-0.1% Tween and
50 µl of a 10 µg/ml solution of anti-M13-pVIII-HRP-con-
jugated antibody (Amersham, USA) in blocking buffer
was added to each well and incubated for 1 h. Plate was
washed and horseradish peroxidase activity was detected
by incubation with 50 µl OPD-substrate (Pierce, USA)
and reaction was stopped by adding 25 µl H2SO4 (1N).
Substrate conversion was read by an automated ELISA
reader and the results were expressed as A = A492 nm-A620
nm.
SDS-PAGE and Western Blot Analysis
25 µl of purified phage samples (5 × 1012 particles/ml) per
lane were separated by 14% SDS-PAGE and transferred to
a nitrocellulose membrane using a Mini Protean III Blot-
ting unit (BioRad, Germany) at 250 mA for 90 min. Mem-
brane was blocked with blocking buffer for 1 h, washed 3
× for 5 min with PBS, then anti-M13-pVIII antibody solu-
tion (1 µg/ml) in blocking buffer was added and incu-
bated for 1 h at RT with gentle shaking. Membrane was
washed 3 times and goat-anti-mouse-HRP-conjugated
antibody in blocking buffer (1 µg/ml) was added fol-
lowed by 1 h incubation at RT. After washing three times
with PBS Western Blots were developed using the CN/
DAB substrate kit (Pierce).
FACS analysis of phagemid particles binding to cell lines
Cells (5 × 105) were washed twice with 1 ml FACS wash
buffer (PBS, 2% FCS, 0.1% NaN3) by centrifugation (300
g) and incubated with 5 × 109 phagemid particles in 100
µl for 1 h at 4°C. Cells were washed twice as described
above and incubated with 100 ng murine anti-M13 anti-
body (Progen, Germany) in 100 µl. Cells were washedPage 9 of 11
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gated goat anti-mouse antibody (Invitrogen, Germany) in
50 µl. Cells were washed and analyzed for green fluores-
cence using a Becton Dickinson FACScanto cytometer and
Becton Dickinson FACSDiva software.
Transduction assays
Cells were seeded at 5 × 104/well in 12-well plates in com-
plete medium and 500 µl phage suspension (4 × 1012
phagemid particles/ml) was added to a total volume of
1.5 ml and incubated for 48 h. After 48 h 1 ml complete
medium was added and cells were incubated for addi-
tional 48 h. EGFP expression was determined by flow
cytometry. To determine the significance of the data, sta-
tistical analysis were performed according to the Student's
one-tailed t test. p-values < 0.05, < 0.01 and < 0.001 were
indicated with *, ** or ***, respectively. For the competi-
tion assay 5 × 104 L1236 cells per well were incubated with
2 × 1011 M13-pAK8-Ki-4(EGFP) phagemid particles in the
absence or presence of 30 nM or 300 nM of the parental
monoclonal antibody Ki-4. After 96 hours cells were ana-
lyzed for EGFP expression by fluorescence microscopy.
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